Can a Test Tell You If You're Perimenopausal?

Blog · Women's Health

Can a Test Tell You If You're Perimenopausal?

By Vitae Team ·

Thirty-one of fifty UK vendors examined sell FSH tests to women over 45, the group NICE says not to test. What a CE mark does and does not cover.

A study published on Tuesday looked at 50 UK companies selling health tests to people with no symptoms, and found that 31 of them offer follicle stimulating hormone tests to all women over 45. That is a notable group to target, because it is the one national guidance says should be identified from symptoms rather than tested. What the kits measure, what the accuracy claims rest on, and what the CE mark on the box covers turn out to be three different questions.

TL;DR

  • Thirty-one of the fifty vendors examined sell FSH tests to all women over 45. NICE advises against routinely using FSH to identify perimenopause in that group.
  • The hormone moves too much for one reading. FSH fluctuates week to week during the transition, which is why guidance leans on months of symptoms instead.
  • A CE or UKCA mark is narrower than most people assume. It covers conformity with device requirements for the stated purpose, not whether the result is clinically useful.
  • Accuracy claims rest on evidence that is often unavailable. Researchers who asked manufacturers for the underlying studies received them for 12 of 30 tests.
  • Two FSH kits claimed over 99% accuracy having been compared against another commercial test, using a sample of mostly women aged 20 to 40.
  • Fourteen of thirty kits told users to see a healthcare professional whatever the result. Nine gave no indication of what should prompt using the test in the first place.
  • Across the wider market, 70% of vendors explained none of the limitations or potential harms of what they were selling.

01 What is being sold, and to whom

The new work comes from Margaret McCartney and colleagues at the University of St Andrews, published in BMJ Open on 17 November and funded by the Laidlaw Foundation. The researchers examined 50 individuals, companies and clinics marketing tests online to healthy people in the UK, covering blood, urine, stool and saliva samples, imaging and physical examinations. Prices ran from £6.99 for a home urine kidney test to £14,000 for a clinic package.

They then set what was on offer against what the NHS recommends, and several categories were being sold to people the NHS does not test. Forty-five vendors offered cholesterol and HbA1c testing to adults under 40. Twenty-eight offered qFIT stool tests to adults under 50. Twelve offered mammograms to women under 50 at normal risk. And 31 offered FSH tests to all women over 45.

Two qualifications belong with that figure. The 50 were selected to map the range of what is on sale rather than to estimate how common each offer is, so 31 of 50 describes this sample and not the UK market. And these tests were marketed to people without symptoms, whereas NICE is addressing how clinicians identify perimenopause in women who have them. The comparison is a fair one, since a woman with symptoms is precisely who buys a menopause test, but the two groups are not identical.

This is not a fringe corner of the market. Thirty-six of the 50 vendors were regulated by the Care Quality Commission, and doctors owned or worked with 41 of them. The sector is forecast to grow from around 1.6 billion US dollars in 2023 to 3.2 billion by 2029. The researchers' conclusion was that gaps in regulation, and particularly the absence of any proactive check on health claims, should be addressed urgently.

02 Why guidance says not to test

NICE guideline NG23 is clear on this. In otherwise healthy women over 45 with typical symptoms, perimenopause and menopause are identified from those symptoms and from changes to the menstrual cycle, without confirmatory laboratory tests. The guideline advises against routinely using FSH for this purpose in that group, and names other tests that should not be used, including anti-Müllerian hormone, oestradiol, antral follicle count and ovarian volume.

The reasoning is the same thing that makes perimenopausal symptoms so hard to read. Oestrogen and FSH do not decline in a smooth line during the transition. They fluctuate, sometimes considerably, from one week to the next. A single measurement describes the morning the sample was taken, which is why clinical guidance rests on a pattern of symptoms over months rather than a number from one day.

The exceptions run in the opposite direction to the marketing. Between 40 and 45, with menopausal symptoms including a change in the cycle, an FSH test may be considered. Under 40, where premature ovarian insufficiency is suspected, diagnosis needs symptoms plus a raised FSH on two separate samples four to six weeks apart, because one is not enough. FSH is also unreliable for anyone taking combined hormonal contraception or a high-dose progestogen. Our Perimenopause Reset sets out what the diagnosis does rest on.

03 What the CE mark on the box covers

Self-test kits are regulated by the MHRA as medical devices, and the usual advice is to look for a CE or UKCA mark. That mark is worth having, and it is also narrower than most people assume. It indicates that a test has been assessed, or declared, to conform to the applicable device requirements, including safety and performance against the purpose its manufacturer states. What it does not establish is that measuring FSH is clinically useful for identifying perimenopause in a woman over 45.

A companion paper from the Birmingham team discussed below looked at what the kits tell people to do with a result, and the answer is often not much. Of the 30 examined, 27 recommended following up with a healthcare professional if the result was positive or abnormal, and 14 recommended following up whatever the result said. Nine gave no indication of the symptoms or risk factors that should prompt using the test at all. A kit that refers a large share of its buyers onward whatever it has just told them is deferring the question rather than answering it.

The MHRA has outlined further reforms, including changes to how self-tests are classified and what performance claims they may make, and has said it is exploring a requirement for published summaries of clinical evidence. Existing rules already govern the safety and performance of these kits, and faults or harm can be reported through the Yellow Card scheme. The researchers' argument is not that nothing is regulated, but that the framework does not proactively scrutinise the health benefits being advertised.

04 What the accuracy claims rest on

The most direct look at the kits themselves came from a team at the University of Birmingham, led by Hillier and colleagues and published in the BMJ in July last year. They bought 30 self-tests from UK supermarkets, pharmacies and health shops, then went looking for the evidence behind them.

Twenty-four of the 30 made accuracy claims in their instructions, and the claims were confident, with more than half of the accuracy figures quoted at 98% or higher. When the researchers asked manufacturers and distributors for the underlying study reports, they received them for 12 of the 30. Three companies declined on grounds of commercial confidentiality and seven did not reply. Of the 15 reports they could assess formally, 73% of the risk-of-bias judgements came out as unclear.

The menopause tests in that sample show what sits behind a number on a box. Two FSH kits claimed to be over 99% accurate across 250 urine specimens, but the comparison was against another commercial test rather than a clinical reference standard, which establishes that two kits agree rather than that either is right. The study population was mostly women aged 20 to 40, while the transition those kits are sold for usually runs from the mid-forties. A third reported 97.14% sensitivity and 93.33% specificity from 65 samples. The researchers also flagged confusing instructions and no clear explanation of what a negative result meant.

Accuracy is not the only thing that has to work. The same team examined each kit, its sampling equipment and its instructions, and rated 18 of the 30 as carrying at least one concern it judged high risk, meaning something that could plausibly produce an erroneous result. The concerns covered equipment, sampling and instructions. That was an appraisal of the kits rather than a test of how people use them. The researchers did not measure the accuracy of the tests they bought and have not run usability studies with the public, so what they describe is a risk that a kit sound in a laboratory goes wrong on a kitchen table rather than a rate at which it does.

What This Actually Means

The honest answer to the question in the headline is that a test can tell you your FSH was high or low on the morning you did it, which is not the same as telling you whether you are perimenopausal. For otherwise healthy women aged 45 or over with typical symptoms, NICE recommends identifying perimenopause from symptoms and menstrual changes rather than routinely measuring FSH. A home test cannot reliably settle a question that a single hormone reading is poorly suited to answering.

What makes this worth writing about is not that the kits are faulty, because most were not shown to be. It is the distance between what regulatory approval covers and what a buyer assumes it covers. Conformity with device requirements is not a finding that the result will help you, and in the Birmingham work nearly half the kits told people to see a clinician whatever the result. Seventy per cent of the vendors in the newer study explained none of the limitations or potential harms.

There is also a quieter cost. When a private test throws up an unexpected result, the follow-up usually lands in NHS primary care, which the St Andrews authors note is already absorbing that work. A test that leaves the user no better informed and sends them to a GP anyway has moved a cost rather than answered a question.

Frequently Asked Questions

Can an FSH test confirm perimenopause?

Not reliably, if you are over 45. NICE says to diagnose from symptoms and cycle changes in that group, because FSH fluctuates too much during the transition for a single reading to mean much.

What does the CE or UKCA mark on the box mean?

That the test has been assessed, or declared, to conform to the applicable device requirements for the purpose its manufacturer states, which rests largely on laboratory performance. It is not an assessment of whether the result is useful to you or improves your care.

Are the accuracy figures on the packaging wrong?

Not necessarily wrong, but frequently unverifiable. Researchers obtained the supporting evidence for only 12 of 30 kits, and two FSH tests claiming over 99% accuracy had been compared against another commercial kit using mostly women aged 20 to 40.

Is there any situation where testing makes sense?

Yes. Between 40 and 45 an FSH test may be considered alongside symptoms, and under 40 it is part of investigating premature ovarian insufficiency, though that needs two samples four to six weeks apart rather than one.

What is more useful than a test?

A record. Six to eight weeks of symptoms, cycles and sleep, one line a day, taken to your GP. That is closer to what the diagnosis is built on than any single hormone reading.

The Bottom Line

Thirty-one of the fifty vendors examined are selling FSH tests to women over 45, the group national guidance says to identify from symptoms rather than test. A separate review of 30 different self-tests found manufacturers making confident accuracy claims and rarely supplying the studies behind them. Its look at the menopause kits raised concerns about what they had been compared against, who was in the comparison, and how the instructions read.

The regulation is doing less than the packaging implies. Conformity with device requirements establishes safety and performance for the stated purpose, not that the number is clinically useful to the person holding the stick. The MHRA has said further reforms to classification and permitted claims are coming, and the researchers' complaint is that nothing checks those health benefits before they are advertised. If you are weighing one up, the question worth asking is what you would do differently depending on the result, and for perimenopause after 45 the answer is usually nothing.

This article is for general information and is not medical advice. If you have symptoms or concerns, speak to your GP.

Sources

  • Mapping the range of tests commercially marketed as screening tests to asymptomatic people in the UK in comparison to those recommended by the NHS: a cross-sectional study. BMJ Open, 17 November 2026. (University of St Andrews; funded by the Laidlaw Foundation.) https://doi.org/10.1136/bmjopen-2026-117741
  • Hillier B, Deeks JJ, Alderman J, et al. Direct-to-consumer self-tests sold in the UK in 2023: cross sectional review of regulation and evidence of performance. BMJ, 2025;390:e085547. https://doi.org/10.1136/bmj-2025-085547
  • National Institute for Health and Care Excellence. Menopause: identification and management (NG23). https://www.nice.org.uk/guidance/ng23/chapter/recommendations
  • Direct-to-consumer self-tests sold in the UK in 2023: cross sectional review of information on intended use, instructions for use, and post-test decision making. BMJ, 2025;390:e085546. https://doi.org/10.1136/bmj-2025-085546
  • Stronger regulatory oversight needed for self-testing kits, review concludes. The Pharmaceutical Journal, 24 July 2025. https://pharmaceutical-journal.com/article/news/stronger-regulatory-oversight-needed-for-self-testing-kits-review-concludes
  • BMJ Group. Many claims for health tests marketed to UK consumers are unsubstantiated, 17 November 2026. https://www.eurekalert.org/news-releases/1151816